Overview

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Status:
NOT_YET_RECRUITING

Trial end date:
2028-08-01

Target enrollment:

Participant gender:

Summary

A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULTS AT HIGH RISK OF DELAYED GRAFT FUNCTION (DGF) FOLLOWING KIDNEY ALLOGRAFT TRANSPLANTATION

Phase:

PHASE3

Details

Lead Sponsor:

Apellis Pharmaceuticals, Inc.

Treatments:

pegcetacoplan